Nonalcoholic steatohepatitis (NASH) Pipeline Analysis” gives comprehensive insight on the various drugs being developed for the treatment of NASH. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins and RNA-based therapeutics, but excludes Off-label, symptom relief drugs, generic combinations. The report also covers hot targets in research for NASH treatments and disease progression biomarkers.
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space.
NASH is associated with fatty liver, hepatic inflammation, hepatocyte injury and fibrogenesis and may worsen into fibrosis or cirrhosis, liver failure and rarely into liver cancer. Currently, there are no approved drugs for NASH by U.S. Food and Drug Administration (FDA) and there a high unmet clinical need. NASH, if untreated can progress to liver-destroying cirrhosis and potentially cancer. Majority of the NASH pipeline drugs are from specialised small to mid pharmaceutical & biotech companies. As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead’s acquisition of Phenex FXR program & Boehringer’s acquisition of NASH clinical asset from Pharmaxis supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH.
In market analysis section, global NASH drugs market is indicated along with the estimated Peak sales ($) of leading clinical stage drugs forecasted from 2018-2024.
- Forecasting model for NASH market
- NASH market dynamics
- NASH Market and estimated Peak sales of 8 clinical candidates (OCA-Intercept, Aramchol-Galmed, Belviq-Arena, Cenicriviroc-Tobira, Simtuzumab-Gilead, Remo Biphasic-Islet, RP103-Raptor, GFT505-Genfit)
- NASH related deals analysis with financials
Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical & development section, pipelines from major companies were identified and Potential targets were reported along with Mechanism of action, Current development status & nature of molecule.
- Pipeline analysis by developmental stage (Discovery to Clinical development)
- Pipeline analysis by modalities
- Monoclonal Antibodies pipeline analysis
- RNA-therapeutics pipeline analysis
- Recombinant protein pipeline analysis
- Pipeline analysis by leading players & Target analysis
- Drug analysis based on mechanism (Anti-Inflammatory, Anti-fibrotic & Metabolic).
IQ4I Research & Consultancy Pvt. Ltd. +91 80 60500229
No- 11, 1st Stage, W. Cord Road http://www.iq4i.com
Rajaji Nagar, Bangalore- 560010, INDIA email@example.com